Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke

Stephanie Bell, Judith Dean, Charles Gilks, Mark A. Boyd, Lisa Fitzgerald, Allyson Mutch, Peter Baker, Graham Neilsen and Coral E. Gartner
Additional contact information
Stephanie Bell: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
Judith Dean: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
Charles Gilks: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
Mark A. Boyd: Lyell McEwin Hospital, University of Adelaide, Haydown Road, Elizabeth Vale, SA 5112, Australia
Lisa Fitzgerald: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
Allyson Mutch: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
Peter Baker: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
Graham Neilsen: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
Coral E. Gartner: School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia

IJERPH, 2017, vol. 14, issue 7, 1-12

Abstract: Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations.

Keywords: smoking; tobacco; HIV; harm reduction; vaporised nicotine; VNPs; e-cigarettes; feasibility (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/14/7/799/pdf (application/pdf)
https://www.mdpi.com/1660-4601/14/7/799/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:14:y:2017:i:7:p:799-:d:105062

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().